financetom
Business
financetom
/
Business
/
McDonald's Q2 Non-GAAP Earnings, Revenue Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
McDonald's Q2 Non-GAAP Earnings, Revenue Rise
Aug 6, 2025 4:34 AM

07:12 AM EDT, 08/06/2025 (MT Newswires) -- McDonald's (MCD) reported Q2 non-GAAP earnings Wednesday of $3.19 per diluted share, up from $2.97 a year earlier.

Analysts polled by FactSet expected $3.14.

Revenue for the quarter ended June 30 was $6.84 billion, compared with $6.49 billion a year earlier.

Analysts polled by FactSet expected $6.7 billion.

The company's shares were up 3% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
TotalEnergies Awarded 4 Exploration Permits Offshore Liberia
TotalEnergies Awarded 4 Exploration Permits Offshore Liberia
Sep 17, 2025
05:29 AM EDT, 09/17/2025 (MT Newswires) -- TotalEnergies (TTE) said Wednesday it has signed four production-sharing contracts for exploration blocks offshore Liberia. The contracts were awarded following a licensing negotiation round last year organized by the Liberia Petroleum Regulatory Agency. The blocks cover around 12,700 square kilometers in the south of the Liberia Basin, the company said, adding that the...
Co-Diagnostics Stock Plunges 28% In Pre-Market Despite Strategic Saudi Partnership
Co-Diagnostics Stock Plunges 28% In Pre-Market Despite Strategic Saudi Partnership
Sep 17, 2025
Co-Diagnostics Inc. ( CODX ) shares dropped 28.26% to $0.46 in pre-market trading on Tuesday, wiping out the gains from Monday’s 80.76% surge, which had closed at $0.64, according to Benzinga Pro data. Check out the current price of CODX stock here. Strategic Partnership Fails to Sustain Momentum The molecular diagnostics firm revealed it has signed a Memorandum of Understanding...
Eli Lilly Says Phase 3 Study of Orforglipron Meets Primary Endpoint
Eli Lilly Says Phase 3 Study of Orforglipron Meets Primary Endpoint
Sep 17, 2025
05:22 AM EDT, 09/17/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Tuesday that a phase 3 study of orforglipron met its primary endpoint, with all three doses of orforglipron demonstrating superior body weight reduction compared with placebo. Orforglipron is the company's investigational oral glucagon-like peptide-1, or GLP-1, receptor agonist and the phase 3 study enrolled adults with obesity,...
Eli Lilly cautious on using FDA fast-track voucher for weight-loss pill
Eli Lilly cautious on using FDA fast-track voucher for weight-loss pill
Sep 17, 2025
VIENNA (Reuters) - Eli Lilly's ( LLY ) international president said on Wednesday it was too early to assume the company would use the U.S. Food and Drug Administration's new fast-track review process for its experimental weight-loss pill orforglipron. There is very little knowledge about this national priority voucher today. I would not assume we will submit with a national...
Copyright 2023-2026 - www.financetom.com All Rights Reserved